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Abstract
In response to pathogen recognition by Toll-like receptors (TLRs) on their cell surface, macrophages release lipid mediators
and cytokines that are widely distributed throughout the body and play essential roles in host responses. Granulocyte
macrophage colony-stimulating factor (GM-CSF) is important for the immune response during infections to improve the
clearance of microorganisms. In this study, we examined the release of mediators in response to TLR2 ligands by bone
marrow-derived macrophages (BMDMs) primed with GM-CSF. We demonstrated that when stimulated with TLR2 ligands,
non-primed BMDMs preferentially produced PGE2 in greater amounts than LTB4. However, GM-CSF priming shifted the
release of lipid mediators by BMDMs, resulting in a significant decrease of PGE2 production in response to the same stimuli.
The decrease of PGE2 production from primed BMDMs was accompanied by a decrease in PGE-synthase mRNA expression
and an increase in TNF-a and nitric oxide (NO) production. Moreover, some GM-CSF effects were potentiated by the
addition of IFN-c. Using a variety of TLR2 ligands, we established that PGE2 release by GM-CSF-primed BMDMs was
dependent on TLR2 co-receptors (TLR1, TLR6), CD14, MyD88 and the nuclear translocation of NFkB but was not dependent
on peroxisome proliferator-activated receptor-c (PPAR-c) activation. Indeed, GM-CSF priming enhanced TLR2, TLR4 and
MyD88 mRNA expression and phospho-IkBa formation. These findings demonstrate that GM-CSF drives BMDMs to present
a profile relevant to the host during infections.
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Introduction
The innate immune response is initiated by microbe recogni-
tion, phagocytosis and activation of numerous cells; macrophages
seem to be at the focal point of this scenario. Through the
production of inflammatory mediators macrophages exert a broad
variety of functions [1]. Murine macrophages have been used as
an important primary cell model for the investigation of the release
and function of pro-inflammatory mediators. Because macrophag-
es are derived from bone marrow cells, this seems a valuable tool
to obtain high numbers of cells from a single mouse [2].
Transgenic and gene-disrupted mice allow the study of particular
mechanisms, which has emphasized the need for cultures of
primary cells, like as BMDM [2]. The specific profile of
metabolites produced by phagocytes depends on the stage of
differentiation, anatomic site of residence [3], and mainly depends
on the activation pathway. The surface expression of receptors and
co-receptors, such as toll-like receptors (TLR), are modulated by
external factors, including cytokines and chemokines, produced in
the microenvironment. The activation of TLR2 pathways by
bacterial and yeast cell wall components is enhanced by GM-CSF
[4]. GM-CSF is also described as a factor for granulocytes priming
for leukotrienes (LTs) synthesis subsequent to stimulation with
chemotactic factors [5]. The increased release of LT results from
GM-CSF priming through increase of arachidonic acid (AA)
release, enhancement of 5-Lipoxygenase (5-LO) activation [6,7]
and rapid augmentation of mRNA translation to increase 5-LO
protein levels [8]. Likewise, when alveolar macrophages (AM) are
stimulated with GM-CSF, the production of LT is increased [9],
validating its role as a primary stimulator of different cell
populations.
GM-CSF is an immune regulatory cytokine produced by
macrophages, endothelial cells, alveolar epithelial cells and T cells
in response to pro-inflammatory cytokines, activating a variety of
cells, such as dendritic cells, neutrophils and macrophages [10].
This cytokine is responsible for the survival, proliferation,
differentiation and function of myeloid cells [11]. The clearance
of microorganisms from the lungs of GM-CSF-deficient mice is
extremely affected [12,13], providing evidence of its importance in
the immune response during infectious diseases. AMs phagocyte a
range of pathogens and particles through mechanisms mediated
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by receptor interactions that can be regulated by GM-CSF
[13,14].
Microbes and their components activate innate immune
responses through interaction of their PAMPs with TLRs. TLR2
recognizes bacterial components, such as peptidoglycan (PGN),
bacterial triacylated lipoprotein (Pam3CSK4), mycoplasma diacy-
lated lipoprotein (Malp2), lipoarabinomannan (AraLAM), zymo-
san and protozoan GPI anchors [15,16,17,18,19,20]. Further-
more, TLR4 is essential for responses to LPS [21]. TLR activation
culminates in the production of cytokines, chemokines, and other
pro-inflammatory molecules to evoke host defense responses and
initiate acquired immunity [22].
Lipid mediators, such as LT and prostaglandins (PG), are widely
recognized for their pro-inflammatory activities [23,24]. PGE2
enhances vasodilation, edema formation and vascular permeability
[24]. LTB4 is a potent chemotactic and chemokinetic mediator
and acts as a leukocyte activator [25]. The role of lipid mediators
during infections has been shown. LT can enhance the phagocytic
activity of neutrophils and macrophages and increase their
capacity to kill microbes and produce antimicrobial mediators
[25]. Moreover,Mycobacterium tuberculosis-infected mice treated with
5-LO pathway inhibitor MK886 have an increased susceptibility
to the disease [26]. This inhibition also results in exacerbation of
pulmonary histoplasmosis [27]. The role of PG in host defense is
also recognized. PGI2 regulates the killing and phagocytosis of
Escherichia coli by alveolar and peritoneal macrophages [28].
Treatment with COX-1/22 inhibitors favor parasitism by
Strongyloides venezuelensis due to a shift in the immune response
[29] and liberation of PGE2 after ingestion of apoptotic cells by
phagocytes results in poor clearance of Streptococcus pneumoniae [30].
However, in contrast to the wealth of data exploring the TLR-
dependent cytokine expression and activation of oxidant produc-
tion, the mechanisms governing the TLR-mediated activation of
lipid mediators production in primary macrophages is unclear.
The production of eicosanoids and the macrophage differentia-
tion/maturation process play an important role in innate
immunity. Here, we address the effect of a set of TLR2-ligands
on the production of PGE2 and LTB4 by GM-CSF primed
BMDM and the correlation with other pro-inflammatory medi-
ators, such as TNF-a and Nitric Oxide (NO).
Methods
Mice
Six- to 8-week old C57Bl/6 mice deficient for TLR2 [17],
TLR1 [31], TLR6 [32], CD14 [33], MyD88 [34] and TLR4 [35]
and their strain-matched wildtype (WT) controls from both sexes
were bred under specific pathogen-free conditions in the
Transgenose Institute animal breeding facility (UPS44, CNRS,
Orleans, France). This study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the Regional ethics committee (Permit
Number: CL2008-011). All surgery was performed under CO2/
O2 excess atmosphere, and all efforts were made to minimize
suffering.
Priming and Stimulation of Primary Macrophage Cultures
in vitro
Murine bone marrow cells were isolated from femurs and
cultivated (106/ml) for 7 days (37uC and 5% CO2) in Dulbecco’s
minimal essential medium (DMEM) supplemented with 10 mM
L-glutamine (Sigma), 100 U/mL penicillin (Invitrogen) and
100 U/mL streptomycin (Invitrogen), 20% horse serum and
30% L929 cell-conditioned medium as a source of macrophage
colony-stimulating factor (M-CSF). After suspending in cold
phosphate-buffered saline (PBS), washing, and re-culturing for
3 days in fresh medium, the cell preparation contained a
homogenous population of macrophages (97–98% CD11b+F4/
80+). The bone marrow derived macrophages (BMDM) were
plated in 48-well microculture plates (Nunc) at a density of 56105
cells/well in DMEM supplemented with 10 mM L-glutamine,
100 U/mL penicillin and 100 U/mL streptomycin and10% fetal
bovine serum (FBS) and cultured at 37uC in a humidified
atmosphere of 5% CO2 for 18 h. BMDM were primed (or not)
with 10% J558L cell-conditioned medium as a source of
granulocyte macrophage colony-stimulating factor (GM-CSF)
(3,5 ng/105 cells) for 24 h before stimulation or in a combination
with interferon-c (IFN-c) (500 UI/ml). Subsequently, BMDM
were stimulated with increased concentrations of TLR-ligands as
AraLAM-MS (lipoarabinomannan from Mycobacterium smegmatis)
(InvivoGen) (5–5000 ng/mL), LM-MS (lipomannan from M.
smegmatis) (InvivoGen) (5–5000 ng/mL), Malp2 (S-(2,3-bisacylox-
ypropyl)-cysteine-GNNDESNISFKEK) (Alexis Biochemicals)
(0,3–300 ng/ml), synthetic bacterial lipopeptide Pam3-CSK4 ((S)-
2, 3-bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-
Lys4-OH)tri-hydrochloride, EMC Microcollections) (5–5000 ng/
ml) or LPS (Escherichia coli, serotype O111:B4; InvivoGen) (50–
1000 ng/ml) diluted in DMEM for 24 h at 37uC in a CO2
atmosphere. To determine the time of stimulation, we performed a
time-response titration experiment and chose 24 h of stimulation
based on a maximal production of TNF-a and NO (data not
shown). Medium (DMEM) was used as negative control. Also, to
neutralize potential endotoxin presence in the stimulus solutions,
they were pretreated with Polymyxin-B (Sigma) at 10 mg/mL for
20 min and then added to the cell culture. In other experiments, to
investigate the participation of peroxisome proliferator-activated
receptor-c PPAR-c, BMDM were treated for 30 min before
stimulation with an antagonist of PPAR-c (GW9662) (Sigma) at
1 mM at 37uC and stimulated with the TLR-ligands above or
infected with BCG (MOI, 1:1) or heat-killed M. tuberculosis H37Rv
(HK H37) (MOI, 1:1) during 24 h. Vehicle (DMSO 0.01% in
DMEM) was used as control. The culture supernatants were
harvested and analyzed immediately or stored at 20uC until
further use. The absence of cytotoxicity of the stimuli was
controlled using the incorporation of MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma).
Cytokine Enzyme-Linked Immunosorbent Assay
Supernatants were harvested and assayed for cytokine content
using the commercially available enzyme-linked immunosorbent
assay reagents for TNF-a and IL-10 (Duoset R&D). The detection
limit for both cytokines was 7 pg/mL.
Nitrite Measurements
Nitrite concentrations in the cell supernatants were measured
using the Griess reaction (3% phosphoric acid, 1% p-aminoben-
zene sulfonamide, 1% N-1-napthyl ethylenediamide) as previously
described [36].
Eicosanoids Measurements
LTB4 and PGE2 concentrations were measured directly in cell-
free supernatant from primary macrophage culture. Eicosanoids
were assayed using enzyme-linked immunoassays according to the
manufacturer’s instructions (Cayman Chemical).
Analysis of gene expression by real-time polymerase
chain reaction (qRT-PCR). Expression of mRNA in BMDM
cells after treatment with GM-CSF for 4, 8 and 18 h was evaluated
using a custom RT2 Profiler PCR Array kit (Qiagen). Total RNA
GM-CSF Drives BMDM to a Pro-Inflammatory Pattern
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from BMDM cells was isolated using the RNeasy Mini kit
(Qiagen), and the reverse transcription of 3 mg of RNA was
performed using the RT2 HT First Strand kit (Qiagen). Each
cDNA sample was processed in 96-well plates containing sets of
pre-defined genes (Tlr1, Tlr6, Tlr4, Tlr2, Cd14, Itgb2, Ticam1,
Ticam2, Alox5, Alox5ap, Ptgs2 and Ptges2), including Actb and Gapdh
as endogenous internal controls in all sets. Amplification was
performed duplicates in an Eppendorf Mastercycler ep realplex 4
(Eppendorf). The 2–DDCt method was used in the analysis of the
RT-PCR data.
Measurement of Total and Phosphorylated Proteins by
ELISA
Following priming and LM (5000 ng/mL) stimulation, 36106
cells were lysed in cell lysis buffer (Cell Signaling Technology). Cell
lysates were analyzed, and proteins were semi-quantified using the
PathScanH total-NFkBp65, phospho-NFkBp65 (Ser536) and total-
IkBa, phospho-IkBa (Ser32) sandwich ELISA kits, according to
the manufacturer’s instructions (Cell Signaling Technology).
Brie’y, the lysates were diluted (10 mg/mL), and 100 mL of
lysate was added to wells pre-coated with primary antibody. The
plate was incubated overnight at 4uC and then washed four times.
After washing the plate, the detection antibody was added to the
wells, and the plate was incubated for 1 h at 37uC. After a second
washing process, horseradish peroxidase (HRP)-linked secondary
antibody was added, and the plate was incubated for 30 min at
37uC. Substrate was added, and the plate was incubated for
30 min at room temperature. Finally, the reaction was stopped,
and the samples were read at an absorbance of 450 gm. The
results were expressed as the percentage of relative expression
(absorbance) of control versus that produced by primed BMDMs
stimulated with LM.
Nuclear Translocation of NFkB
BMDM were adhered to cover slides and cultured for 18 h at
37uC in a humidified atmosphere of 5% CO2. Cells were
primed with GM-CSF for 24 h and subsequently stimulated
with TLR2-ligands as described above for 2 h at 37uC and 5%
CO2. Next, the monolayer was washed by gentle agitation with
PBS, fixed in 4% paraformaldehyde, permeabilized with Triton
X-100 (0.5%) and used for immunolocalization of NFkB as
described [37], with minor modifications. BMDM were
incubated with goat anti-murine NFkBp65 antibody (Santa
Cruz Biotechnology) for 1 h at room temperature, washed, and
incubated with swine anti-goat IgG FITC Ab (Sigma). Cells
presenting NFkB nuclear translocation were scored by confocal
microscopy (Leica SP2).
Statistical Analysis
Results were expressed as mean 6 SEM. Statistical significance
was determined with Graph Pad Prism software (Version 4.0, San
Diego, CA) by unpaired t-test analysis of variance. Values of
p,0.05 were considered statistically significant.
Results
1. GM-CSF Priming Reduces Macrophage Production of
PGE2
We characterized the capacity of different TLR2 ligands
derived from bacteria to induce the release of PGE2 and LTB4
from macrophage after priming with GM-CSF. Cells were primed,
or not primed, with GM-CSF and then stimulated with the TLR-
agonists AraLAM, LM, Malp2, Pam3-CSK4 or LPS TLR4 ligand
as a positive control. As shown in Figure 1A, unprimed
macrophage stimulated with AraLAM, LM, Malp2, Pam3-CSK4
and LPS produced high levels of PGE2 as compared with the
negative control; however, the response to AraLAM stimulation
was slightly weaker. GM-CSF priming resulted in a significant
decrease in PGE2 production by stimulated macrophages. The
kinetics of stimulation was similar to all ligands, with the
maximum response obtained after 24 h of incubation (data not
shown). Macrophage priming with GM-CSF resulted in a small
increase in LTB4 release as compared with unprimed cells
(Fig. 1B). However, GM-CSF priming did not affect TLRs
induced LTB4 production (Fig. 1B). Similarly, no effect of GM-
CSF priming was observed on LTC4 release after TLR-agonist
stimulation in the same conditions (data not shown). Thus, GM-
CSF priming decreased PGE2 release by TLR-activated macro-
phages.
2. GM-CSF Priming Enhances TLR2 Ligands-induced TNF-
a and NO Release
The effects of GM-CSF priming on macrophage release of
TNF-a and NO in response to TLR2 or TLR4 stimulation
were further analyzed. Macrophages were treated with increas-
ing concentrations of TLR-ligands for 24 h. A time-dependent
Figure 1. GM-CSF-modified lipid mediators released by BMDM
in response to bacterial TLRs-ligands. BMDM from WT mice were
primed (or not) with GM-CSF for 24 h and then incubated with AraLAM
(5000 ng/mL), LM (5000 ng/mL), Malp2 (300 ng/mL), Pam3-CSK4
(5000 ng/mL) or LPS (500 ng/mL) for 24 h. PGE2 (A) and LTB4 (B)
release were measured in the supernatant by ELISA. Medium alone was
used as a negative control. Results are the average 6 S.E.M from mice
cells (n= 6 per group), from two independent experiments; *, p,0.05
compared with unstimulated cells; #, p,0.05 compared with non-
priming GM-CSF cells.
doi:10.1371/journal.pone.0040523.g001
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increase in TNF-a and NO, which peaked after incubation for
24 h, was observed (data not shown). Therefore, in all
subsequent experiments, TNF-a and NO was measured at this
time point. We also evaluated the concentration-dependent
effect of TLR-ligands and observed that Malp2 (Fig. 2D), LM
(Fig. 2B) and Pam3-CSK4 (Fig. 2C) induced maximal responses
at 300 ng/ml, 5000 ng/mL and 5000 ng/mL, respectively.
Priming with GM-CSF induced an increase of the peak TNF-
a release, obtained at these concentrations. Moreover, AraLAM
induced significant concentrations of TNF-a only at 5000 ng/
mL (Fig. 2A). GM-CSF priming also greatly increased LPS-
induced TNF-a release (Fig. 2E).
AraLAM (Fig. 3A), LM (Fig. 3B) and Malp2 (Fig. 3D) induced
no or only a weak production of NO in unprimed cells, but NO
release was increased synergistically after GM-CSF priming. In
addition, LPS (Fig. 3E) and Pam3-CSK4 (Fig. 3C) stimulated NO
release dose-dependently and a significant enhancement in NO
release was also observed after GM-CSF priming.
The capacity of TLR2 to recognize a vast array of compounds
has been attributed to the ability of TLR2 to heterodimerize with
other TLR co- and accessory receptors, which defines their ligand
specificity [38]. The TLR2 co-receptors include TLR1 and TLR6.
In addition, recognition of TLR2 agonists is influenced by several
accessory receptors, including CD14 [39]. Most TLRs, including
TLR2, recruit the MyD88 adaptor molecule, which leads to the
induction of downstream signaling events through activation of
nuclear factor NFkB and mitogen-activated protein (MAP) kinases
[40,41].
To further identify whether TLR1, TLR6, CD14 and MyD88
are involved in the signaling pathway of NO and TNF-a
Figure 2. Effect of GM-CSF priming on TNF-a secretion by BMDM. BMDM from WT mice were primed (or not) with GM-CSF for 24 h and then
incubated for 24 h with increasing concentrations of AraLAM (5–5000 ng/mL) (A), LM (5–5000 ng/mL) (B), Pam3-CSK4 (5–5000 ng/mL) (C), Malp2
(0.3–300 ng/mL) (D) or LPS (50–1000 ng/mL) (E). Medium alone was used as a negative control. Supernatants were harvested, and ELISA was used to
determine the cytokine content. Results are the average 6 S.E.M from mice cells (n= 6 per group), from two independent experiments; *, p,0.05
compared with unstimulated cells; #, p,0.05 compared with non priming GM-CSF cells.
doi:10.1371/journal.pone.0040523.g002
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production by GM-CSF primed macrophages, we analyzed the
TLR pathway dependence in macrophages from gene-deficient
mice. Low concentrations of TNF-a (Table 1) were produced by
GM-CSF-primed TLR22/2 and CD142/2 macrophages after
stimulation with AraLAM and LM. In contrast, after Malp2 and
Pam3-CSK4 stimulation, TNF-a was efficiently released by GM-
CSF-primed CD142/2 but not by TLR22/2 macrophages. In the
absence of either TLR1 or TLR6, there was a partial decrease in
TNF-a release following Pam3-CSK4 stimulation, but TNF-a
release was totally abolished in GM-CSF-primed TLR62/2
macrophages stimulated with Malp2. As expected LPS-indu-
ced TNF-a release was essentially absent in GM-CSF-primed
TLR42/2 or CD142/2 macrophages. TNF-a production was
strongly impaired or not detected in the supernatants of
MyD882/2 macrophages in the presence of all stimuli used
(Table 1). Similarly, the induction of NO (Table 2) by AraLAM,
LM, Malp2 and Pam3-CSK4 was strongly dependent on TLR2
and MyD88. In addition, NO release by GM-CSF-primed
macrophages stimulated with LM was dependent on CD14 but
dependent on TLR6 when stimulated with Malp2. As described,
LPS stimulation was totally dependent on CD14 and TLR4 and
partially dependent on MyD88 (Table 2). Therefore, GM-CSF
priming did not alter the TLR pathway usage for macrophage
TNF and NO release.
Figure 3. Effect of GM-CSF priming on NO production by BMDM. BMDM from WT mice were primed (or not) with GM-CSF for 24 h and then
incubated for 24 h with increasing concentrations of AraLAM (5–5000 ng/mL) (A), LM (5–5000 ng/mL) (B), Pam3-CSK4 (5–5000 ng/mL) (C), Malp2
(0.3–300 ng/mL) (D) or LPS (50–1000 ng/mL) (E). Medium alone was used as a negative control. Supernatants were harvested, and the Nitrite content
determined by the Griess Method. Results are the average 6 S.E.M from mice cells (n= 6 per group), from two independent experiments; *, p,0.05
compared with unstimulated cells; #, p,0.05 compared with unprimed GM-CSF cells.
doi:10.1371/journal.pone.0040523.g003
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3. PGE2 Induced by TLR2 Ligands Depend on Co-
receptors and MyD88
The participation of TLR pathways in the production of PGE2
by GM-CSF-primed macrophages was then evaluated in macro-
phages from gene deficient mice. After stimulation with AraLAM,
a significant increase in PGE2 production was observed in GM-
CSF-primed macrophages cultures from C57Bl/6, CD142/2,
TLR12/2, TLR62/2 and TLR42/2 mice, while this effect was
abrogated in GM-CSF-primed, TLR22/2 macrophages (Fig. 4A).
Furthermore, LM stimulated PGE2 release from WT macrophag-
es, but the absence of TLR2 dramatically reduced this effect
(Fig. 4A). Macrophages deficient for TLR6 responded to LM as
efficiently as WT cells, but the production of PGE2 was reduced in
TLR12/2 (Fig. 4B) and CD142/2 (Fig. 4A) macrophages. MalP-2
induction of PGE2 was reduced in GM-CSF primed, TLR2
2/2,
CD142/2 (Fig. 4A), TLR62/2 (Fig. 4B) or TLR42/2 (Fig. 4C)
macrophages. GM-CSF primed, TLR22/2 macrophages showed
a severely impaired response to Pam3-CSK4 stimulation (Fig. 4A)
while no significant difference in PGE2 production was observed in
TLR12/2 or TLR62/2 macrophages (Fig. 4B). GM-CSF primed,
TLR42/2 cells showed an impaired production of PGE2 when
stimulated with LPS (Fig. 4C), as expected. All of the TLRs
evaluated in this work signal through MyD88, and our results
clearly indicate the participation of this adaptor protein in the
production of PGE2 after GM-CSF priming (Fig. 4C). Therefore,
macrophage GM-CSF priming did not alter TLR pathway
requirement for PGE2 release.
4. Regulation of mRNA Expression of the Enzymes
Involved in PGE2 and LTB4 Metabolism, TLRs and TLR
Adaptor Molecules in GM-CSF-primed BMDMs
To determine the effects of GM-CSF on steady-state mRNA
encoding for 5-LO, FLAP, COX-2, PGE2 synthase, TLR1,
TLR2, TLR4, TLR6, CD14, MyD88, TRIF and TRAM,
macrophages were cultured with or without GM-CSF for various
periods of time and without agonist stimulation. Quantitative real
time polymerase chain reaction (qRT-PCR) analysis from these
BMDMs revealed that GM-CSF priming increased COX-2
mRNA expression (threefold) after 4 h of incubation (Fig. 5A),
and this increase persisted through 8 h (fivefold) (Fig. 5B) and 18 h
(fourfold) (Fig. 5C) of incubation. In contrast, PGE2 synthase
mRNA was down-regulated 4 h after GM-CSF treatment and
persisted until 18 h. No effect was observed on mRNA for either
5-LO or FLAP after 4 h of incubation, compared with non-treated
macrophages (Fig. 5A). However, there was an approximately
half-fold increase in mRNA for 5-LO but not for FLAP at 8 h of
GM-CSF treatment (Fig. 5B). As shown in Fig. 5B, we detected
increased mRNA expression of TLR2 and TLR4 only after 8 h of
GM-CSF treatment. There was no effect on mRNA expression for
TLR1 and TLR6. However, CD14 mRNA expression was down-
regulated within 18 h of GM-CSF treatment. Since the use of
different adaptor proteins provides a mechanism to modulate the
response of individual TLRs, we analyzed the regulation of the
expression of known TLR adaptor protein stimulation. TRAM
mRNA expression is up-regulated after 4 h of treatment (Fig. 5A),
which was associated with elevated MyD88 and TRIF mRNA
expression after 8 h of GM-CSF treatment (Fig. 5B). Thus, GM-
CSF coordinately regulates the expression of multiple molecular
components of the innate response in macrophages, including
both positive (COX-2, 5-LO, TLR2, TLR4, MyD88, TRIF and
TRAM) and negative (PGE2 synthase and CD14) components.
5. TLRs and Co-receptors Participate in IL-10 Production
by Macrophages Stimulated with Bacterial Products
In addition to their participation in the production of pro-
inflammatory mediators, TLR-ligands are also involved in the
regulation of IL-10 release, as shown in Figure 6. Macrophages
primed with GM-CSF constitutively produced relatively low
concentrations of IL-10. Stimulation with LM, Pam3-CSK4 and
LPS resulted in IL-10 secretion. However, AraLAM and Malp2
had a very small effect on IL-10 induction (data not shown).
Subsequently, the impact of TLRs and co-receptors on IL-10
production after GM-CSF priming was examined. As shown in
Figure 6A, IL-10 secretion by LM-stimulated WT primary
macrophages was inhibited in TLR22/2, CD142/2 and
MyD882/2 cells. Indeed, TLR22/2, TLR12/2 and
MyD882/2 cells were largely unresponsive to Pam3-CSK4 in
terms of IL-10 release, and TLR62/2 macrophages were partially
responsive (Fig. 6B), while absence of TLR4 and MyD88
prevented LPS induced IL-10 release (Fig. 6C). Thus, bacterial
PAMPs, including mycobacterial LM, induce IL-10 release in
GM-CSF primed macrophages.
6. IFN-c Potentiates the Effects of GM-CSF
IFN-c is added in culture to prime macrophage. To analyze the
effect of GM-CSF in combination with IFN-c on macrophage
priming, the production levels of TNF-a, IL-10, NO and PGE2
were determined in cell culture supernatants after stimulation with
TLR ligands. Macrophages were primed with GM-CSF only or in
combination with IFN-c. For all TLRs ligands tests NO release
was increased after priming with a combination of GM-CSF and
IFN-c (Fig. 7A). Priming with either GM-CSF or IFN-c induced a
Table 1. Effect of GM-CSF priming on TNF-a production by BMDM in response to bacterial stimulusa.
Stimulus TLR22/2 TLR12/2 TLR62/2 TLR42/2 CD142/2 MyD882/2
AraLAM 99.360.4b 1.7610.2c 24.4612.3c 33.6612.5 76.662.2b 99.560.1b
LM 89.962.9b 21.660.2c 27.164.8c 36.865.0b 69.361.5b 92.960.6b
Malp2 99.760.3b 15.861.5 99.160.5b 13.461.8 11.2623.6 99.760.1b
Pam3 99.061.2
b 44.063.2b 35.060.2b 15.960.7 20.863.8c 99.760.2b
LPS 221.3617.4c 219.7614.5c 219.561.7c 99.760.7b 79.161.3b 94.360.1b
aBMDM from WT (C57Bl/6) or deficient mice (2/2) for TLR2, TLR1, TLR6, TLR4, CD14 and MyD88 primed with GM-CSF, were incubated with AraLAM (5000 ng/mL), LM
(5000 ng/mL), Malp2 (300 ng/mL), Pam3-CSK4 (5000 ng/mL) or LPS (500 ng/mL) for 24 h in vitro. TNF-a was measured by ELISA. Percentage of inhibition of TNF-a
production in deficient mice compared to WT.
bp,0.05, significantly versus WT production. Data are mean 6 S.D, n = 6 mice per genotype from two independent experiments.
cNegative values corresponds an increment in correlation with WT production.
doi:10.1371/journal.pone.0040523.t001
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comparable TNF-a release in response to the TLR ligands (data
not shown). However, priming with the combination of GM-CSF
plus IFN-c did not result in a further increase in TNF-a release as
compared to the single priming with GM-CSF, at the concentra-
tions of stimuli used (Fig. 7B). Surprisingly, PGE2 (Fig. 7C) and IL-
10 (Fig. 7D) production by macrophages primed with both GM-
CSF and IFN-c significantly decreased in response to AraLAM,
LM, Malp2, Pam3-CSK4 or LPS exposure, compared to priming
with GM-CSF alone. Thus, IFN-c priming potentiates GM-CSF
induced increase in NO and decrease in PGE2 and this is
associated with a decrease in IL-10 release.
7. The Effects of GM-CSF Priming on NFkB Nuclear
Translocation and PPAR-c Activation Upon TLR2
Stimulation
NFkB is an inducible transcription factor that plays a central
role in the regulation of inflammation. In resting cells, NFkB is
maintained in an inactive form in the cytoplasm by association
with IkB, but after cell stimulation, IkB is phosphorylated,
allowing NFkB to be translocated into the nucleus and to become
active. To determine whether GM-CSF priming and stimulation
with TLR2 ligands are associated with the activation of NFkB, we
analyzed total cytoplasmic NFkBp65, phosphorylated (phospho)
NFkBp65, total IkBa, and phospho-IkBa in BMDM lysate after
priming the cells with GM-CSF, IFN-c or GM-CSF plus IFN-c in
the presence or absence of LM stimulus (2 h) using PathScanH
ELISA. The results showed that all priming had no effects on total
and phospho-NFkBp65 expression (Fig. 8A) or total and phospho-
IkBa expression (Fig. 8B). The LM stimulus up-regulated total and
phospho-NFkBp65 but had no effect on total and phospho-IkBa
expression. Priming with GM-CSF or GM-CSF plus IFN-c
enhanced the total and phospho-NFkBp65 expression after LM
stimulation. Indeed, these priming conditions also enhanced
phospho-IkBa expression. However, the priming with only IFN-
c increased phospho-NFkBp65 but not phospho-IkBa expression
after LM stimulation. The nuclear translocation of NFkBp65 was
confirmed by immunofluorescence. NFkBp65 staining is cytoplas-
mic in GM-CSF-primed macrophages before TLR ligand
stimulation. After 2 h of stimulation with AraLAM, LM, Malp2,
Pam3-CSK4 or LPS, the translocation to the nucleus was clear
(Fig. 8, panel). The stimuli also significantly increased the
percentage of cells showing nuclear NFkBp65 staining, as
compared with the untreated cells (Fig. 8C).
Considering that lipid-activated nuclear receptors may play an
important role in macrophage differentiation and in the inflam-
matory response, we next examined the influence of PPAR-c
inhibition on TNF-a and PGE2 production by TLR-stimulated
macrophages primed with GM-CSF using a specific PPAR-c
antagonist (GW9662). Primed macrophages were pre-treated with
GW9662 and then stimulated with AraLAM, LM, Malp2, Pam3-
CSK4, and LPS, using heat-killed M. tuberculosis H37Rv (HK H37)
and M. bovis BCG as positive controls. Pre-treatment with the
PPAR-c antagonist GW9662 had no effect on the production of
TNF-a (Fig. 8C) and PGE2 (Fig. 8D) in primed macrophages after
stimulation. Therefore, NFkB, but not PPAR-c, seems to be
involved in the GM-CSF-primed macrophage response to TLR2
and TLR4 agonists, resulting in TNF-a, NO and PGE2 release.
Discussion
Macrophages have a pivotal function in the resolution of
infectious diseases. The activation of macrophage receptors
induces intracellular signaling that results in the release of
mediators into the microenvironment. GM-CSF is a multifunc-
tional cytokine that has a primary role as a hematopoietic growth
factor. In addition, GM-CSF can directly activate and have a
priming effect on mature phagocytes [42,43]. TLRs interact with
different combinations of adapter proteins and activate transcrip-
tion factors, leading to specific immune responses when activated
by structurally conserved molecules derived from pathogens
[44,45]. Here, we analyzed the mechanisms governing TLR-
mediated eicosanoid production by BMDMs primed with GM-
CSF. Primarily, our study demonstrated that priming BMDMs
with GM-CSF and stimulating BMDMs with TLR ligands results
in a downregulation of PGE2 production. In contrast, these
primed cells have increased TNF-a and NO release. The
production of pro-inflammatory mediators by GM-CSF-primed
BMDMs is dependent on the adaptor protein MyD88 and the
nuclear translocation of NFkBp65.
As an activator of cell functions, GM-CSF has been shown to
upregulate LTs release by alveolar macrophages (AM) in rats [9].
When pre-treated with GM-CSF, AMs released more AA and
generated more metabolites, including PGs and LTs upon
subsequent stimulation, compared to untreated cells. This action
was related to the capacity of GM-CSF to increase the expression
of the 85-kDa PLA2 protein, an important enzyme in the
eicosanoid production pathway [9]. Here, priming with GM-CSF
resulted in a reduction of PGE2 release by BMDMs stimulated
with different TLR2 ligands (AraLAM, LM, Malp2 and Pam3-
CSK4) or the TLR4 ligand LPS. Although this reduction was
accompanied by an increase in COX-2 mRNA expression, PGE-
synthase mRNA expression was downregulated at the time of the
analyses, and this downregulation may have led to the decrease in
Table 2. Effect of GM-CSF priming on NO production by BMDM in response to bacterial stimulusa.
Stimulus TLR22/2 TLR12/2 TLR62/2 TLR42/2 CD142/2 MyD882/2
AraLAM 55.666.9b 210.0630.3c 12.4627.9 35.266.8b 34.2639.5 98.462.1b
LM 79.0610.1b 225.8623.7c 5.8622.5 17.365.3 67.362.1b 83.061.8b
Malp2 90.662.2b 1.8615.2 87.868.0b 226.864.5c 31.7619.6 97.563.1b
Pam3 91.560.4
b 5.264.3 21.5615.1 222.061.9c 9.964.7 98.560.4b
LPS 7.2627.7 226.0622.3c 20.4614.0c 99.360.9b 71.663.3b 55.466.0b
aBMDM from WT (C57Bl/6) or deficient mice (2/2) for TLR2, TLR1, TLR6, TLR4, CD14 and MyD88 primed with GM-CSF, were incubated with AraLAM (5000 ng/mL), LM
(5000 ng/mL), Malp2 (300 ng/mL), Pam3-CSK4 (5000 ng/mL) or LPS (500 ng/mL) for 24 h in vitro. NO (Nitrite) was measured in the supernatants by Griess Method.
Percentage of inhibition of NO production in deficient mice compared to WT.
bp,0.05, significantly versus WT production. Data are mean 6 S.D, n = 6 mice per genotype from two independent experiments.
cNegative values corresponds an increment in correlation with WT production.
doi:10.1371/journal.pone.0040523.t002
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PGE2 production. Several reports demonstrated that PGE2
contributes to immune suppression [46]. PGE2 secreted from
activated macrophages in response to pro-inflammatory stimuli
acts on macrophages themselves and exhibits an inhibitory
function in a negative feedback loop [47,48]. Therefore, we
suggest that GM-CSF acted as a regulator for an inflammatory
profile. The biosynthesis of LTs in macrophages is known to result
from a complex series of reactions. These particular events begin
with the activation of transmembrane receptors by cytokines or
other stimuli that prompt the activation and expression of 5-LO
and the entire signaling pathway, resulting in the production of
LTB4 and cysteinyl leukotrienes (Cys-LT). Here, although the
effect of GM-CSF priming on BMDM release of LTB4 was
demonstrated and 5-LO mRNA expression was upregulated in
BMDMs after 8 h of GM-CSF priming, no further increase in
LTB4 was observed after stimulation with TLR2 ligands or LPS.
These results suggest that there is additional regulation at other
levels in the 5-LO pathway and may reflect the activation/
Figure 4. TLRs, co-receptors and MyD88 contribute to PGE2 production by GM-CSF primed BMDM. BMDM from WT (C57Bl/6) or mice
deficient for TLR2 or CD14 (A), TLR1 or TLR6 (B), or TLR4 or MyD88 (C) were primed with GM-CSF for 24 h and then incubated for 24 h with AraLAM
(5000 ng/mL), LM (5000 ng/mL), Malp2 (300 ng/mL), Pam3-CSK4 (5000 ng/mL) or LPS (500 ng/mL) in vitro. Medium alone was used as negative
control. ELISA was used to measure the PGE2 production in the supernatants. Results are the average 6 S.E.M (n= 6 per genotype), from two
independent experiments; *, p,0.05 compared with unstimulated cells; #, p,0.05 compared with WT mice.
doi:10.1371/journal.pone.0040523.g004
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deactivation of the cell signaling response to a stimulatory assay
[49].
Priming with GM-CSF was also critical for the formation of NO
by BMDMs. In GM-CSF-primed macrophages, the level of NO
production was strongly increased with all the stimuli evaluated.
The increase in NO production may contribute to the decrease in
PGE2 release. NO has been reported to suppress COX activity
and PGE2 production [50]. The modulation of the COX system
by NO represents an important pathway that regulates the
magnitude of the inflammatory process [51]. There is molecular
crosstalk between the inflammatory mediators NO and PGs. NO
exerts divergent effects on the constitutive and inducible COX
isoforms, activating COX-1 but inactivating COX-2 [52].
Moreover, COX-2 nitration inhibits the catalytic activity of this
enzyme [53]. Interestingly, other reports suggest that LPS reduces
5-LO metabolism by multiple mechanisms, including the marked
induction of NO synthase (NOS) [54]. NO has been proposed to
inactivate lipoxygenases by reducing the ferric enzyme to the
ferrous form [55]. This effect of NO on 5-LO and COX-2
inactivation is another possible mechanism for the lower
production of LTB4 and the decreased PGE2 production by
GM-CSF-primed BMDMs after TLR-ligand stimulation.
Different from that observed with PGE2, GM-CSF-primed
BMDMs subsequently stimulated with TLR ligands produced
higher concentrations of TNF-a, as compared with unprimed
cells. These data confirm the results of a study demonstrating that
the main priming factor for TNF-a release by human PMNs was
GM-CSF [56]. We suggest that the increase in cytokines release
after priming with GM-CSF could be a consequence of a series of
events, such as an increase in TLR2 and TLR4 mRNA expression
and an increase in mRNA expression of TRIF-related adaptor
molecule (TRAM) and MyD88. However, IL-10 production in
response to LM, Pam3-CSK4 or LPS was reduced in GM-CSF-
primed macrophages (data not shown). Our results demonstrate
that GM-CSF priming enhances phospho-IkBa expression after
TLR2 agonist stimulation and that IFN-c potentiates this
Figure 5. Effect of GM-CSF priming on BMDM mRNA expression. mRNA was prepared from 56106 BMDMs. Macrophages were treated with
or without GM-CSF for 4 (A), 8 (B) or 18 h (C). qRT-PCR was used to determine the relative expression of transcripts encoding for lipid metabolism
enzymes, TLRs and adaptor proteins. The results were normalized to the expression of the endogenous internal controls Actb and Gapdh. The 2–DDCt
method was used in the analysis of the qRT-PCR data. Dotted lines show mRNA expression in untreated cells. The results are presented as the average
6 S.E.M from three independent experiments in duplicate (n = 3); *, p,0.05 compared with non-GM-CSF-treated cells.
doi:10.1371/journal.pone.0040523.g005
Figure 6. Evidence of the involvement of TLRs, CD14 andMyD88, in IL-10 production by BMDM primed with GM-CSF. BMDM from WT
mice or mice deficient were primed with GM-CSF for 24 h and then stimulated with LM (5000 ng/mL), Pam3-CSK4 (5000 ng/mL) or LPS (500 ng/mL)
for 24 h. The concentrations of IL-10 from BMDM deficient for TLR2, CD14 or MyD88 stimulated with LM (B), deficient for TLR2, TLR1, TLR6 and MyD88
stimulated with Pam3-CSK4 (C) and deficient for TLR2, TLR4 and MyD88 stimulated with LPS (D) were determined in the culture supernatant. Medium
alone was used as a negative control. ELISA was used to determine the concentrations of IL-10. Results are the average 6 S.E.M (n= 6 per genotype),
from two independent experiments; *, p,0.05 compared with unstimulated cells; #, p,0.05 compared with WT mice.
doi:10.1371/journal.pone.0040523.g006
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phenomenon. Increased IkBa phosphorylation and elevated levels
of nuclear NFkB components p50 and p65 by GM-CSF-priming
was also demonstrated in monocytes [43].
We addressed the effect of GM-CSF priming in combination
with IFN-c in macrophage stimulation. IFN-c is a major activation
signal for macrophages. The priming or concomitant exposure of
macrophages to IFN-c dramatically increases their responsiveness
to microbial products, such as LPS, in terms of the production of
NO, cytokines and co-stimulatory molecules [57]. Macrophage
priming with the combination of GM-CSF and IFN-c had no
effect on TNF-a release, possibly because priming with GM-CSF
alone was able to induce the maximal production of this cytokine
at the doses of agonists that were used. However, NO production
was increased in the presence of IFN-c, demonstrating its
importance on cell signaling to activate NO metabolism in
macrophages. As expected, with increased concentrations of NO,
there was decreased PGE2 and IL-10 production by BMDMs
primed with the combination of GM-CSF and IFN-c, in
comparison to BMDMs primed with GM-CSF alone. Indeed,
GM-CSF and IFN-c have immunostimulatory properties; they not
only prime resting monocytes but also restore monocytic functions
after LPS tolerization [58].
The concept of TLR-ligand interactions suggests that individual
TLR proteins recognize a set of microbial products [40]. Some
TLR proteins may act cooperatively in response to particular
microbial ligands [38]. In studies of neutrophil priming, the
expression of TLR2 and CD14 was upregulated by GM-CSF or
LPS treatment [4]. Our results showed that TLR2 and TLR4
expression by BMDMs controlled the potential response to
microbial ligands and that this response was dramatically
enhanced by GM-CSF priming, suggesting that GM-CSF can
modulate the activation of macrophages in the host defense against
bacterial infection. The mycobacterial lipoglycans LM and
AraLAM are structural parts of the mycobacterial cell wall that
interact with pattern recognition receptors, such as TLRs [19].
AraLAM and LM from several mycobacteria display pro-
inflammatory activities [59,60], whereas ManLAM has a predom-
inant anti-inflammatory activity in the presence of the TLR4
agonist LPS [61,62]. In our experiments, we used LM and
AraLAM purified from M. smegmatis, and we described the pattern
of recognition of GM-CSF-primed BMDMs by TLR2, TLR1,
TLR6, TLR4 and CD14 agonists. The release of TNF-a from
AraLAM-stimulated cells in culture is mediated through TLR2
and CD14. However, NO production and PGE2 production are
mediated by only TLR2. As we demonstrated here, LM
stimulation of PGE2 formation occurs by activating a complex
cluster of receptors mediated through CD14, TLR2 and TLR1,
which may function as heterodimers. The lipopeptides induce
signaling in the cells of the immune system through TLR2–TLR1
or TLR2–TLR6 heterodimers [63,64]. We show that Malp2
stimulation of GM-CSF-primed macrophages results in a marked
increase in pro-inflammatory mediator production. Malp2 stim-
Figure 7. IFN-c potentiates the GM-CSF priming effects on BMDM. BMDM WT cells were preincubated for 24 h with GM-CSF or GM-CSF plus
IFN-c (500 UI/mL) and then stimulated with AraLAM (5000 ng/mL), LM (5000 ng/mL), Malp2 (300 ng/mL), Pam3-CSK4 (5000 ng/mL) or LPS (500 ng/
mL) for 24 h in vitro. The supernatants were analyzed for the production of NO (Nitrite) (A), TNF-a (B), PGE2 (C) and IL-10 (D). Medium alone was used
as a negative control. ELISA was used to measure TNF-a and PGE2, and the Griess Method was used to measure Nitrite production in the
supernatants. Results are the average 6 S.E.M from mice cells (n= 6 per group) from two independent experiments; *, p,0.05 compared with
unstimulated cells; #, p,0.05 compared with GM-CSF priming alone.
doi:10.1371/journal.pone.0040523.g007
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ulation of PGE2 release is strongly dependent on TLR2–TLR6
and the adaptor protein MyD88 in GM-CSF-primed macrophag-
es, while Pam3-CSK4 stimulation of PGE2 release depends mostly
on the TLR2 and MyD88 pathway.
NFkB plays a central role in the regulation of many of the genes
responsible for the generation of inflammatory mediators. [65].
Therefore, NFkB is an attractive candidate to mediate the release
of pro-inflammatory mediators. Our data show that BMDMs
primed with GM-CSF and stimulated with TLR2 ligands express
a very prominent nuclear staining of NFkBp65 and phospho-
NFkBp65 relative expression. Peroxisome proliferator activated
receptors (PPARs) are members of the nuclear hormone receptor
superfamily of ligand-activated transcription factors [66]. Myco-
bacteria-induced PPAR-c expression and activation are demon-
strated to be centrally involved in regulating lipid metabolism in
macrophages through the modulation of lipid body biogenesis and
PGE2 production, thereby affecting the host response to infection
[67]. We hypothesized that the activation of PPAR-c has an effect
on PGE2 release by macrophages. However, PPAR-c inhibition by
GW9662 treatment did not affect TNF-a and PGE2 release in
response to TLR agonists, heat-killed M. tuberculosis, or BCG
infection.
Together, our results demonstrate that GM-CSF priming of
BMDMs enhances the capacity to drive the pro-inflammatory
Figure 8. Nuclear translocation of NFkB and PPAR-c activation in BMDMs primed with GM-CSF. NFkBp65, IkBa expression and NFkB
nuclear translocation were investigated in BMDMs from WT mice. Graphic (A) percentage of relative expression of total NFkBp65, phosphorylated
NFkBp65, (B) total IkBa and phosphorylated IkBa compared with non-stimulated control cell lysate (dotted line). Cells were pre-incubated for 24 h
with GM-CSF, IFN-c or GM-CSF plus IFN-c and then stimulated with LM (5000 ng/mL) for 2 h in vitro. Total cellular proteins were collected to assay the
relative expression by ELISA (PathScan Sandwich ELISA kit). The percentage of positive cells for NFkB nuclear translocation is shown for macrophages
primed with GM-CSF for 24 h and then stimulated with different TLR2 agonists or LPS for 2 h, as analyzed by confocal microscopy. The panel depicts
the expression of nuclear NFkB in GM-CSF primed BMDMs stimulated with medium (vii), AraLAM (viii), LM (ix), Malp2 (x), Pam3-CSK4 (xi) or LPS (xii)
and the contrast DIC (i, ii, iii, iv, v and vi) on immunofluorescence slides. To evaluate the role of PPAR-c in pro-inflammatory mediator release, WT
primary macrophages were treated with 1 mM of PPAR-c antagonist (GW 9662) 1 h before stimulus. TNF-a (C) and PGE2 production (D) after 24 h of
incubation were measured directly in the supernatant by ELISA. The graphic results are the average 6 S.E.M for cells (n= 6 per group) from two
independent experiments; *, p,0.05 compared with unstimulated cells. The images from confocal microscopy were representatives from two
independent experiments.
doi:10.1371/journal.pone.0040523.g008
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response against bacterial components by increasing TNF-a and
NO production and by altering lipid mediator release. In
particular, the production of PGE2, which was more prominent
than that of LTB4, was strongly decreased by GM-CSF priming,
indicating a compensatory function for these cells in a high
inflammatory environment. Our data suggest that the GM-CSF
produced when a host is infected by a pathogen may be
responsible for the macrophages exhibiting a pro-inflammatory
profile. Additionally, GM-CSF drives host immune defense
mechanisms, which favor phagocytosis and killing, as a result of
a shift in the production of lipid mediators from PGE2 to LTB4.
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